A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-19. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== Storage == MenAfriVac remains stable for 4 days under 40 °C (104 °F). As a result the WHO has cleared it for controlled temperature chain use, which means that MenAfriVac vaccination drives are allowed be conducted even when there is no refrigeration at the point of care.
complete encasement in concrete square column. wrapping the i-beam in a thin layer of metal lath and then covering it with gypsum plaster. This method is effective because gypsum plaster contains water crystals that are heat resistant. applying multiple layers of gypsum board around the i-beam. applying spray-on fireproofing around the i-beam. Also called spray-applied fire-resistive materials (SFRM) using air pressured spray gun, which can be made from gypsum plaster, mineral fibers mixed with inorganic binder or a cementitious formula using magnesium oxychloride cement. enclosing the i-beam in sheet metal and fill with loose insulation. hollow columns filled with liquid water or antifreeze. When part of the column is exposed to fire, the heat is dissipated throughout by the convection property of the liquid. encasing the i-beam in rigid concrete slab. a layer of suspended plaster ceiling isolating the i-beam
==== 2025 ==== UPF1 was found to decline significantly during cellular senescence. The findings suggest that the fall in UPF1 accelerates senescence by slowing down nonsense-mediated mRNA decay. The study was conducted by scientists at Chungnam National University, the Korea Research Institute of Bioscience and Biotechnology, the Korea Advanced Institute of Science and Technology, and the US National Institute on Aging. Scientists at the University of California, Berkeley managed to extend the lifespans of elderly male mice by 73% with a 14% increase in overall lifespan with the Alk5 inhibitor OT+A5i. Researchers at RWTH Aachen University discovered that four senolytic compounds – JQ1, RG7112, nutlin-3a, and AMG232 – can decrease epigenetic age in in vitro blood samples. Researchers at the University of Osaka discovered that the protein AP2A1 may regulate cellular senescence, finding that suppressing the protein in older cells reversed senescence and promoted rejuvenation, whereas overexpression of the protein in young cells advanced senescence. A study by scientists at University College London, Stanford University, Inserm, and the University of Helsinki found that accelerated aging in specific organs could be predictors for diseases across the entire body, not just those affecting that particular organ. A study at the University of Texas at Austin identified the exposure of osteocytes to senescent cells as a key driver of aging in bones.
Sources: en.wikipedia.org
=== 21 July === President Zelenskyy claimed that one Ukrainian soldier killed is killed for every six to eight wounded. Russian losses, according to him, were one killed for every two to three wounded. A Russian platoon commander from an unidentified Russian motor rifle brigade claimed in an interview that his brigade, with an established strength of 6,000 personnel, had lost 12,000 killed or wounded in Ukraine, or 200% of its strength. Sabotage organised by HUR damaged three helicopters, namely an Mi-8, Ka-226 and an Mi-28, at the JSC Russian Helicopters facility in Moscow.
Alternatively some may use titles specific to the discipline they train in, such as "trainee clinical biochemist", "clinical immunologist in training" or "pre-registrant clinical microbiologist", which is also acceptable since it is not implying the protected "clinical scientist" title of fully qualified and registered practitioners. It is against the law to formally work with the title of "clinical scientist" without professional registration.
Buprenorphine is an opioid used to treat opioid use disorder, acute pain, and chronic pain. It is administered under the tongue, in the cheek, by injection (intravenous or subcutaneous), or as a skin patch or implant. Maximum pain relief generally occurs within an hour and lasts up to 24 hours. In the United States, buprenorphine/naloxone (Suboxone) is usually prescribed to discourage injection misuse. Both formulations are Schedule III controlled substances. Buprenorphine acts as an agonist, partial agonist, or antagonist at different opioid receptors. It relieves opioid withdrawal and reduces the effects of other opioids. Unlike full agonists such as heroin and methadone, it has a ceiling effect for some effects, including respiratory depression, but retains misuse potential. Side effects include respiratory depression, sleepiness, adrenal insufficiency, QT prolongation, low blood pressure, allergic reactions, constipation, and opioid addiction. It may increase seizure risk in susceptible people; opioid withdrawal after discontinuation is generally less severe than with other opioids. Safety during pregnancy is unclear, but use while breastfeeding is probably safe: infants receive approximately 1–2% of the maternal weight-adjusted dose. The compound acts as a partial agonist of the μ-opioid receptor (MOR), exhibiting approximately 48% maximal efficacy in the reported functional assay. Its signaling profile is biased toward G-protein-mediated signaling, with comparatively weak recruitment of β-arrestins.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.